Treatment of non - tuberculosis mycobacteria lung disease is challenging. The current treatment used is from 2007 American Thoracic Society guidelines recommended antibiotic combination therapy, which is lack of validation of clinical studies. More and more studies have confirmed that NTM antibiotic resistant gene will affect the efficacy, such as erm(41), rrl to clarithromycin, rrs to amikacin and so on. This study aimed to compare the efficacy of guideline recommended therapy and optimized therapy according to antibiotic susceptibility - related genotype.Genetic testing is accomplished through GenSeizer's high-throughput gene capture technique.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
246
The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
Haiqing Chu
Shanghai, China
RECRUITINGCulture conversion rate
The proportion of final sputum conversion to culture negative
Time frame: up to 18 months
Initial time of sputum culture conversion
The time of first sputum conversion to culture negative
Time frame: up to 18 months
Chest CT
Chest imaging changes of CT examination
Time frame: up to 18 months
Blood routine test
Time frame: every month, up to 18months
liver function test
Time frame: every month, up to 18months
kidney function test
Time frame: every month, up to 18months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.